Fennec Pharmaceuticals Ord Shs FENC

Primary Symbol: T.FRX

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs > IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

<< Previous

Bullboard Posts

Next >>

Comment by willyk3on Dec 13, 2021 8:05am

249 Views

Post# 34224219

RE:RE:IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

The obvious solution at this stage is to just sell the darn company (at a discount) to a real pharmaceautical company who has the capability to complete the process

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023